Gold bars to be exempt from tariffs, White House clarifies
Radiopharm Theranostics Ltd (ASX:RAD), a company focused on developing radiopharmaceutical products for cancer treatment, announced new preclinical data for its Lu177-B7H3-mAb therapy. The announcement was made on the Australian Securities Exchange today.
The report, titled "RAD Reports Preclinical Lu177-B7H3-mAb Data," details findings from recent studies. These studies are part of the company’s ongoing efforts to develop targeted therapies for cancer treatment, utilizing radiopharmaceuticals that combine radioactive elements with molecules that specifically target cancer cells.
Radiopharm Theranostics, headquartered in Carlton, Victoria, Australia, is working on therapies that aim to improve the precision and effectiveness of cancer treatment by using radiolabeled antibodies. These antibodies are designed to bind to specific proteins found on the surface of cancer cells, delivering targeted radiation to destroy them while minimizing damage to surrounding healthy tissue.
The company has not yet disclosed specific details about the outcomes of the preclinical studies or the next steps in the development process. The data was shared as part of a Form 6-K filing with the U.S. Securities and Exchange Commission, which included the public notice released to the Australian Securities Exchange.
Radiopharm Theranostics is classified under the pharmaceutical preparations industry and continues to explore innovative approaches in the field of cancer treatment. The company is not currently furnishing the information for purposes of the Securities Exchange Act of 1934, according to the filing.
The release of this data marks a step forward in Radiopharm Theranostics’ research and development activities, as it seeks to advance its pipeline of radiopharmaceutical therapies. The company’s focus remains on leveraging its expertise in radiopharmaceuticals to address unmet needs in oncology.
This information is based on a press release issued by Radiopharm Theranostics Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.